文献速递哮喘

重度哮喘ILC2增殖增强且受生物制剂调节

Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics.
PubMed 文献 · Respirology · 2023-04-28

研究比较健康对照、非哮喘过敏、轻度哮喘和重度过敏性嗜酸性哮喘患者外周血ILC2的增殖能力、IL-5/IL-13分泌及表型,并评估美泊利珠单抗或奥马利珠单抗治疗6个月对重度哮喘ILC2生理的影响。结果显示重度哮喘ILC2增殖增强、TSLPR/GATA3/NFATc1表达升高、IL-5/IL-13/IL-6释放增加;美泊利珠单抗降低ILC2增殖及TSLPR/GATA3/NFATc1表达,两种生物制剂均降低IL-5/IL-13,仅美泊利珠单抗降低IL-6。

要点

  • 重度过敏性嗜酸性哮喘患者ILC2呈活化表型,增殖及2型细胞因子释放增强。
  • 美泊利珠单抗可降低ILC2增殖及TSLPR、GATA3、NFATc1表达。
  • 美泊利珠单抗和奥马利珠单抗均降低ILC2释放IL-5和IL-13。

核心结论

  • 重度过敏性嗜酸性哮喘患者ILC2呈活化表型,表现为增殖增强、TSLPR/GATA3/NFATc1表达升高及IL-5、IL-13、IL-6释放增加。
  • 美泊利珠单抗治疗可降低ILC2活化标志物。

研究设计与样本

  • 研究比较健康无哮喘(HC)、非哮喘过敏(NAA)、轻度哮喘(MA)和重度过敏性嗜酸性哮喘(SA)受试者外周血分离的ILC2。
  • ILC2在IL-2、IL-25、IL-33和TSLP存在下培养14天,用流式细胞术评估增殖、表型和功能。
  • 随后重新评估SA受试者经美泊利珠单抗或奥马利珠单抗临床成功治疗6个月后的ILC2反应。

主要发现

  • SA的ILC2增殖能力增强,TSLPR、GATA3和NFATc1蛋白表达增加,IL-5和IL-13释放增加。
  • ILC2在刺激下也能释放IL-6。
  • 美泊利珠单抗治疗降低ILC2增殖能力及TSLPR、GATA3和NFATc1表达。
  • 美泊利珠单抗和奥马利珠单抗均与ILC2释放IL-5和IL-13减少相关,仅美泊利珠单抗降低IL-6。

临床怎么用

  • 重度过敏性嗜酸性哮喘患者ILC2活化表型可作为生物制剂治疗反应的潜在监测指标。
  • 美泊利珠单抗治疗可降低ILC2增殖及活化标志物表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Type 2 (T2) innate lymphoid cells (ILC2s) contribute to airway inflammation and disease in asthma. We hypothesize that ILC2s isolated from people with severe allergic and eosinophilic asthma would exhibit an enhanced T2 inflammatory activity that would be altered following treatment with mepolizumab and omalizumab. We compare peripheral blood (PB) isolated ILC2's proliferative capacity, IL-5 and IL-13 secretion and phenotype between healthy without asthma (HC), non-asthma allergic (NAA), mild asthma (MA) and severe allergic and eosinophilic asthma (SA) subjects. We then determined the impact of 6 months treatment with either mepolizumab or omalizumab on ILC2s physiology of SA subjects. METHODS: ILC2s were sorted and cultured in the presence of IL-2, IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) for 14 days. ILC2s proliferation, phenotypes and functions were assessed using flowcytometry. The ILC2s response was then reassessed following clinically successful treatment of SA subjects with mepolizumab and omalizumab. RESULTS: SA ILC2s demonstrated increased proliferative capacity, TSLP receptor (TSLPR), GATA3 and NFATc1 protein expressions and increased IL-5 and IL-13 release. ILC2s were also capable of releasing IL-6 in response to stimulation. Mepolizumab treatment reduced ILC2s proliferative capacity and expression of TSLPR, GATA3 and NFATc1. Both mepolizumab and omalizumab were associated with reduced ILC2s release of IL-5 and IL-13, only mepolizumab reduced IL-6. CONCLUSION: ILC2s from severe allergic and eosinophilic asthma demonstrated an active phenotype typified by increased proliferation, TSLPR, GATA3 and NFATc1 expression and increased IL-5, IL-13 and IL-6 release. Mepolizumab reduced markers of ILC2s activation.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Malik B, Bartlett NW, Upham JW, et al. Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics. Respirology. 2023. PMID: 37114915. doi:10.1111/resp.14506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。